150,000 square foot state-of-the-art operations facility adds manufacturing scale and capacity
PLEASANTON, Calif., May 23, 2023 — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, celebrated today the grand opening of its newest facility in Pleasanton.
The 150,000 square foot space is part of an expansion initiated in 2021 to strengthen the company’s manufacturing and operations scale and infrastructure with additional capacity for future growth. The new site further expands the company’s existing Pleasanton campus, which now totals approximately 450,000 square feet and includes its global headquarters and a cutting-edge R&D center opened last year.
“From our earliest days in a neighborhood garage to today’s opening of our new U.S. operations hub, 10x has been proud to call Pleasanton home for more than 10 years,” said Ben Hindson, Co-founder, President and Chief Scientific Officer of 10x Genomics, Inc. “This new site enables us to maintain close proximity and collaboration between our operations and R&D teams, fueling our innovation engine as we strive to deliver more new products to researchers faster and help accelerate their scientific discoveries and tomorrow’s medical advances. We are thankful to the City of Pleasanton for their partnership and for the incredible talent available in the East Bay, and we look forward to continuing our growth as part of this vibrant and innovative community.”
Through the expansion of 10x’s Pleasanton campus, the company will increase collaboration and knowledge-sharing among its approximately 675 local employees in manufacturing, operations, R&D, commercial and administrative functions. The new property located at 5500 Stoneridge Mall Road is equipped with state-of-the-art clean rooms for product manufacturing, warehouses including high-tech cold chain facilities, and supporting office spaces and amenities. The new building was also designed to meet LEED Gold level environmental and sustainability standards.
“Pleasanton is fortunate to have companies that recognize the value of investing in our community, and I am thrilled that 10x Genomics is one such company,” said Pleasanton Mayor Karla Brown. “They started here, grew here, and with the opening of their new headquarters campus have committed to stay and be an integral part of our city. We are proud to attract and support game-changing companies in Pleasanton and extend congratulations to the entire 10x team.”
About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2021 based on publications and all of the top 20 global pharmaceutical companies by 2021 research and development spend and have been cited in over 5,000 research papers on discoveries ranging from oncology to immunology and neuroscience. Our patent portfolio comprises more than 1,750 issued patents and patent applications.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should,"”enables,” "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s expectations regarding closer collaboration and knowledge-sharing, potential impact on innovation, anticipated increased delivery of new products, including our expectations regarding the acceleration of researchers scientific discoveries and future medical advances. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. These forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments 10x Genomics may make. Further, such forward-looking statements may not accurately or fully reflect the potential impact of adverse geopolitical and macroeconomic events, difficulties selling in APAC, product capabilities and adoption rates, international economic, political, legal, compliance, social and business factors, such as the COVID-19 pandemic, inflation, supply chain that may have on the business, financial condition, results of operations and cash flows of 10x Genomics, Inc. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com